Background: Group 2 innate lymphoid cells (ILC2s) are a potential innate source of type 2 cytokines in the pathogenesis of allergic conditions. Epithelial cytokines (IL-33, IL-25, and thymic stromal lymphopoietin [TSLP]) and mast cell mediators (prostaglandin D2 [PGD2]) are critical activators of ILC2s. Cysteinyl leukotrienes (cysLTs), including leukotriene (LT) C4, LTD4, and LTE4, are metabolites of arachidonic acid and mediate inflammatory responses. Their role in human ILC2s is still poorly understood. Objectives: We sought to determine the role of cysLTs and their relationship with other ILC2 stimulators in the activation of human ILC2s.

Methods: For ex vivo studies, fresh blood from patients with atopic dermatitis and healthy control subjects was analyzed using flow cytometry. For in vitro studies, ILC2s were isolated and cultured. The effects of cysLTs, PGD2, IL-33, IL-25, TSLP, and IL-2 alone or in combination on ILC2s were defined by using chemotaxis, apoptosis, ELISA, Luminex, quantitative RT-PCR, and flow cytometric assays. The effect of endogenous cysLTs was assessed by using human mast cell supernatants.

Results: Human ILC2s expressed the LT receptor CysLT1, levels of which were increased in atopic subjects. CysLTs, particularly LTE4, induced migration, reduced apoptosis, and promoted cytokine production in human ILC2s in vitro. LTE4 enhanced the effect of PGD2, IL-25, IL-33, and TSLP, resulting in increased production of type 2 and other proinflammatory cytokines. The effect of LTE4 was inhibited by montelukast, a CysLT1 antagonist. Interestingly, addition of IL-2 to LTE4 and epithelial cytokines significantly amplified ILC2 activation and upregulated expression of the receptors for IL-33 and IL-25.

Conclusion: CysLTs, particularly LTE4, are important contributors to the triggering of human ILC2s in inflammatory responses, particularly when combined with other ILC2 activators. (J Allergy Clin Immunol 2017;140:1090-100.)

Key words: Group 2 innate lymphoid cell, leukotriene E4, prostaglandin D2, IL-25, IL-33, IL-2, thymic stromal lymphopoietin, atopic dermatitis

Group 2 innate lymphoid cells (ILC2s) are recognized as an innate source of type 2 cytokines in the pathogenesis of allergic conditions, such as asthma and atopic dermatitis. ILC2s are known to be lymphoid effector cells that do not express rearranged antigen-specific receptors but express CD45, IL-7 receptor α, and chemotactic receptor-homologous molecule expressed on TH2 cells (CRTH2) while lacking lineage markers, including CD3, T-cell receptor (TCR) αβ, TCRγδ, CD14, CD19, CD56, CD11b, and CD11c. Although they can be found in various anatomical locations, their enrichment in mucosal surfaces of the lung, gut, and skin implies a local immunologic role. ILC2s contribute to allergic and inflammatory conditions by producing IL-4, IL-5, IL-13, and GM-CSF. In the gut ILC2s are a source of type 2 cytokines for efficient expulsion of the helminth Nippostrongylus brasiliensis. In the lungs they induce airway hyperresponsiveness and epithelial repair after influenza infection.

ILC2s not only respond to the epithelial cytokines IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) but also respond to the mast cell lipid mediator prostaglandin D2 (PGD2). It has also been reported that murine ILC2s respond to another group of lipid mediators, cysteinyl leukotrienes (cysLTs), to produce type 2 cytokines, although the effect of cysLTs in human ILC2s is still unclear.

CysLTs, including leukotriene (LT) C4, LTD4, and LTE4, are formed from arachidonic acid metabolism. At the nuclear envelope, cytosolic phospholipase A2 liberates membrane arachidonic acid, which binds to 5-lipoxygenase–activating protein. 5-Lipoxygenase catalyzes the formation of LTA4 by adding an oxygen moiety to arachidonic acid. Activated inflammatory cells, such as eosinophils, basophils, mast cells, and alveolar macrophages, possessing LTC4 synthase can synthesize LTC4 rapidly through conjugation of LTA4 with reduced glutathione levels. After extracellular export, LTC4 is...
converted to LTD₄ and then LTE₄ by means of sequential removal of the glutamic acid moiety, followed by the glycine moiety. LTD₄ is the most potent airway muscle contractant with the shortest half-life (in minutes); in contrast, LTE₄ is stable and the dominant LT detected in biological fluids. Monitoring LTE₄ levels in urine, sputum, and exhaled air is an index of the activity of the cysteiny1 leukotriene (cysLT) synthesis pathway. The surge in cysLT production asso-
ciated with inflammatory conditions, such as asthma, allergic rhinitis, urticaria, and other inflammatory conditions, has been well studied. We reported previously that cysLTs have been characterized and designated as cysteiny1 leukotriene receptor 1 (CysLT₁), with high binding affinity for LTD₄, and cysteiny1 leukotriene receptor 2 (CysLT₂), with similar affinity for LTD₄ and LTC₄, but both receptors have low affinity for LTE₄. Other potential receptors for LTE₄ include adenosine diphosphate–reactive purinoreceptor P2Y₁₂ with the highest homology to CysLT₁ (32%) and GPR99.

CysLT₁ mediates bronchoconstriction and also a range of proinflammatory effects, including activation and migration of leukocytes. CysLT₂, antagonists, most notably montelukast, are used to control asthma and allergic rhinitis. Definition of the role of cysLTs and their receptors in human ILC2s will improve our understanding of the pathogenic mechanisms of ILC2-mediated allergic inflammation and indicate potential novel therapeutic strategies.

In this study we explored the effect of cysLTs and their receptors on human ILC2s, particularly when combined with other ILC2 stimulators. We investigated whether human ILC2s express functional CysLT₁ and whether expression is increased by ILC2s from patients with atopic dermatitis. We assessed the effects of cysLTs on cytokine production, migration, and apoptosis of cells in the presence and absence of the CysLT₁ antagonist montelukast. Finally, we assessed whether cysLTs show a synergistic effect with PGD₂ and epithelial cytokines in activating the cells. Our study provides a broad understanding of the role of cysLTs in ILC2-mediated inflammatory responses, particularly in mixed inflammatory environments.

METHODS

**ILC2 cell preparation and culture**

Human ILC2s were prepared from human blood from healthy donors and cultured by using a modified method, as described previously. Briefly, PBMCs were isolated by using Lymphoprep gradients (Axis-Shield UK, Dundee, United Kingdom). CD3⁺ T cells were predepleted with CD3 microbeads, and the remaining cells were labeled with an antibody mixture. Lineage (CD3, CD14, CD19, CD56, CD11b, CD11c, TCRαβ, TCRγδ, FcεRI, and CD123)–negative, CD45RO⁺, CD127⁺, and CRTH2⁺ cells were sorted on a FACSAria III cell sorter (BD Biosciences, San Jose, Calif) and cultured for 5 to 6 weeks in RPMI 1640 containing 100 IU/mL IL-2, 10% heat-inactivated human serum, 2 mmol/L L-glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin in the presence of gamma-irradiated PBMCs (from 3 healthy volunteers). Half of the medium was refreshed every 2 to 3 days. The cells were changed to fresh medium without IL-2 before treatment. Most ILC2s used in the study were derived from healthy donors, except where indicated specifically.

Adult (30-88 years) patients with atopic dermatitis received a diagnosis based on the United Kingdom refinements of the Hanifin and Rajka diagnostic criteria, and the disease severity score was defined by using SCORAD. None of the patients were receiving systemic therapy at the time of the sample acquisition. Use of human tissue samples was approved ethically by the Oxford Clinical Research Committee.

**Human mast cell culture and activation**

Human mast cells were cultured from CD34⁺ progenitor cells and treated with human IgE and goat anti-human IgE in the presence or absence of MK886, as described previously. Cell supernatants were collected and LTE₄ levels were measured with an ELISA, or the supernatants were stored at −80°C until used as mast cell supernatants for the treatment of ILC2s.

**Chemotaxis assays**

Cell migration assays were conducted, as described previously. Briefly, ILC2s (approximately 5 × 10⁶ cells/well) and treatment reagents were loaded into the upper and lower chambers, respectively, in a 5-μm pore–sized ChemoTx plate (Neuro Probe, Gaithersburg, Md). After incubation for 1 hour, migrated cells in the lower chambers were treated with a Cell Titer-Glo Luminescent Cell Viability Assay Kit (Promega, Madison, Wis) and quantified by using a FLUOstar OPTIMA luminescence plate reader (BMG LabTech, Cary, NC).

**Apoptosis assay**

ILC2s (approximately 5 × 10⁵ cells per condition) were harvested after different treatments and transferred to annexin-binding buffer, followed by incubation with phycoerythrin–Annexin V/propidium iodide at room temperature, according to the manufacturer’s instructions (Invitrogen, Carlsbad, Calif). The stained cells were analyzed with an LSR Fortessa flow cytometer (BD Biosciences).

**Multiplex bead array**

After treatment for 4 hours, concentrations of selected cytokines in the supernatants of ILC2 cultures were measured with a Human Premixed Multi-Analyte Kit (R&D Systems, Minneapolis, Minn) with magnetic beads, according to the manufacturer’s instructions. Results were obtained with a Bio-Plex 200 System (Bio-Rad Laboratories, Hercules, Calif).

**Quantitative RT-PCR**

Quantitative RT-PCR was conducted, as described previously. Primers and probes (Roche, Mannheim, Germany) are listed in Table E1 in this article’s Online Repository at www.jacionline.org.

**ELISA**

Concentrations of cytokines in the supernatants of ILC2 cultures were assayed with ELISA kits (R&D Systems). LTE₄ levels in supernatants of mast cells were assayed with an ELISA.
CysLTs promote survival of human ILC2s

LTs contribute to eosinophil and neutrophil survival during inflammatory responses. We next examined the effect of cysLTs on ILC2 survival using an apoptosis assay. Removal of IL-2 led to a dramatic increase in the number of Annexin V-positive ILC2s (Fig 3, A). The increase in Annexin V binding was reduced by LTD4 (50 nmol/L) or LTE4 (50 nmol/L) within 20 hours. However, because of the degradation of early apoptotic cells, the precise potency of cysLTs on ILC2 apoptosis beyond 24 hours could not be determined. The prosurvival effect of cysLTs on ILC2s was concentration dependent, with a half maximal inhibitory concentration at 4, 36, and 1.8 nmol/L for LTC4, LTD4, and LTE4, respectively (Fig 3, B). LTE4 was more potent in inhibiting ILC2 apoptosis. In contrast, no effect of cysLTs on ILC2 proliferation was detected (see Fig E3 in this article’s Online Repository at www.jacionline.org). The antiapoptotic effect of cysLTs was abolished by montelukast (Fig 3, C).

CysLTs induce production of type 2 cytokines by human ILC2s

One of the important proinflammatory roles of cysLTs is enhancing type 2 cytokine production. To investigate this effect in human ILC2s, we incubated ILC2s with increasing concentrations of LTC4, LTD4, and LTE4. All LTs enhanced IL-13 production in a dose-dependent manner with a similar half maximal effective concentration: 4 ± 1.5, 4.1 ± 1.9, and 3.9 ± 1.1 nmol/L for LTC4, LTD4, and LTE4, respectively (Fig 4, A). Other type 2 cytokines (IL-4 and IL-5) were also induced by cysLTs (Fig 5, data not shown). Because LTE4 induced greater responses than LTC4 and LTD4 by ILC2s, we subsequently focused on LTE4. The effect of montelukast was examined to investigate the role of CysLT1 on the cytokine production induced by cysLTs. Montelukast exhibited dose-dependent inhibition, with a half maximal inhibitory concentration at 0.24 nmol/L for 100 nmol/L LTE4 treatment (Fig 4, B). Ten to 30 nmol/L was required to completely abolish the effect of LTE4 on cytokine production.

LTE4 enhances the effect of PGD2 and epithelial cytokines on activation of human ILC2s

Our previous report demonstrated that PGD2 could stimulate the production of multiple cytokines (IL-3, IL-4, IL-5, IL-8, IL-13, GM-CSF, and macrophage colony-stimulating factor [CSF1]) by human ILC2s. The cells were treated with these lipids alone or in combination to further understand the effect of combinations of cysLTs and PGD2 on ILC2s. Compared with PGD2, LTE4 only weakly increased production of IL-4, IL-5, IL-8, IL-13, GM-CSF, CSF1, and amphiregulin (Fig 5, A). The combination of LTE4 and PGD2 exhibited synergistic (IL-4, IL-8, IL-8, GM-CSF, CSF1, and amphiregulin) or additive (IL-5 and IL-13) enhancement of cytokine production. The effect associated with LTE4 was removed by montelukast. mRNA levels of type 2 cytokines were measured by using quantitative RT-PCR to confirm the synergistic effect of LTE4 and PGD2 at the gene level. The combination of LTE4 and PGD2 showed further enhancement in gene transcription levels compared with LTE4 or PGD2 alone (see Fig E4 in this article’s Online Repository at www.jacionline.org).
Next, we measured the synergistic effect of LTE₄ and epithelial cytokines. Treatment with IL-33, IL-25, and TSLP alone for 4 hours showed only very weak induction of cytokine production by ILC2s (Fig 5, B). However, addition of IL-33, IL-25, or TSLP to LTE₄ significantly augmented cytokine production (IL-4, IL-5, IL-8, IL-13, GM-CSF, CSF1, and amphiregulin). The greatest enhancement was seen when IL-25, IL-33, and TSLP were used in combination with LTE₄. Intracellular staining for type 2 cytokines in ILC2s ex vivo also confirmed this enhancing effect (see Fig E5 in this article’s Online Repository at www.jacionline.org). Montelukast abrogated the effect of LTE₄. IL-2 is a critical cofactor in regulating ILC2 function in patients with lung inflammation. To understand the role of IL-2 in human ILC2 cytokine production, we compared cell treatments in the presence or absence of IL-2 (Fig 6). IL-2 alone had no detectable effect on the production of most cytokines. However,
it slightly enhanced the cytokine production induced by LTE4 and epithelial stimulators alone and significantly enhanced the cytokine production induced by the combination of LTE4 and other stimulators, including the combination of LTE4 with all 3 epithelial cytokines (IL-33, IL-25, and TSLP; Fig 6, A, and see Fig E6 in this article’s Online Repository at www.jacionline.org). Inhibition of CysLT1 abolished the synergistic enhancement. The effect of IL-2 was further confirmed at the level of gene expression (see Fig E7 in this article’s Online Repository at www.jacionline.org).

To further investigate the potential mechanism involved in the synergistic enhancement of ILC2 activation by the combination of LTE4 with other stimulators, we examined the mRNA levels of the relevant receptors CYSLT1, PTGDR2, IL1RL1, IL17RA, IL17RB, and IL2RA after treatment (Fig 6, B). Although PTGDR2 (CRTH2) was strongly downregulated and CYSLT1 and IL17RB were partially downregulated by the combined stimulations, IL17RA, IL2RA, and IL1RL1 were upregulated. Upregulation of IL1RL1 was particularly strong and showed strong correlation with cell activation detected based on cytokine production (see Fig E8 in this article’s Online Repository at www.jacionline.org).

**Endogenous cysLTs from activated human mast cells stimulate ILC2s**

CysLTs are major lipid mediators produced by mast cells.29 The effect of endogenously synthesized cysLTs from activated human mast cells on ILC2s was examined to confirm the role of cysLTs in ILC2 biology under physiologic conditions (Fig 7). Only low levels of LTE4 (approximately 6 ng/2 × 10⁶ cells/mL) were detectable in supernatants from resting mast cells (Fig 7, A). Treatment with IgE followed by anti-IgE antibody cross-linking of mast cells produced high LTE4 levels (approximately 86 ng/2 × 10⁶ cells/mL). Cotreatment of IgE/anti-IgE–activated mast cells with MK886 (10 μmol/L), an inhibitor of 5-lipoxygenase–activating protein, during the period of anti-IgE stimulation abolished LTE4 production (approximately 7.9 ng/2 × 10⁶ cells/mL). Use of these supernatants to treat ILC2s revealed that the supernatant from IgE/anti-IgE–activated mast cells but not that of resting mast cells induced production of IL-5 and IL-13 (Fig 7, B). The type 2 cytokine production induced by the mast cell supernatant was partially but significantly inhibited by montelukast. Blocking cysLT synthesis in mast cells with MK886 also partially reduced the capacity of the supernatant to induce cytokine production by ILC2s. A similar effect was observed at the mRNA level (Fig 7, C).
mediator PGD2 as important stimulators for ILC2s. Although innate epithelial cytokines IL-33, IL-25, and TSLP and the lipid mediator PGD2 are important stimulators for ILC2s, they are not the only regulators. LTE4 showed the highest efficacy among cysLTs in human ILC2s, suggesting an important proinflammatory role of cysLTs in human ILC2 activation. They promoted cytokine production, induced cell migration, and reduced apoptosis by ILC2s. These effects were also seen in response to endogenous cysLTs from human mast cells. LTE4 showed the highest efficacy among cysLTs in human ILC2 biology, and the effects were blocked by the CysLT1 antagonist montelukast. The activation of ILC2s was significantly amplified when treated with cysLTs combined with PGD2 and epithelial cytokines, particularly in the presence of IL-2, suggesting an important proinflammatory role of cysLTs in ILC2-mediated immune responses in the presence of other ILC2 stimulators.

LTs are potent proinflammatory lipids predominantly derived from activated mast cells and basophils. Their biological functions are mediated through binding to a group of G protein-coupled receptors: CysLT1 and CysLT2. Because both receptors have only low affinity for LTE4 based on ligand-binding assays, the potent activity of LTE4 in human ILC2s suggested to us a potential CysLT1/CysLT2-independent mechanism. P2Y12 and GPR99 have been proposed as receptors with a preference for LTE4, but we found that neither is expressed in ILC2s. A recent report demonstrated that CysLT1 is critically important for responsiveness to LTE4 within certain types of human cells. This could be the case for human ILC2s because (1) human ILC2s express high levels of CysLT1, (2) LTE4 showed higher efficacy than LTD4 in human ILC2s, and (3) the activity of LTE4 in human ILC2s was completely inhibited by montelukast. This phenomenon has also been observed previously in human T\textsubscript{h}2 cells. However, we still cannot rule out the possibility of involvement of another unknown LTE4 receptor. If such a putative receptor exists, our data suggest that it should be responsive to montelukast. Mouse ILC2s also express CysLT1. However, in contrast to the findings in human ILC2s, the effect of LTE4 in mice seems weaker than that of LTD4. Furthermore, the IL-5–producing ILC2s induced by LTE4 administered in vivo cannot be inhibited by montelukast in mouse models (although this interaction was not dissected in vitro). These between-species differences in the effects of LTE4 on ILC2s might be consistent with involvement of a novel LTE4 receptor.

The level of CysLT\textsubscript{1} in human ILC2s is upregulated in cells from patients with atopic dermatitis, suggesting a potential pathogenic role of cysLTs/CysLT1 in patients with the disease. Several studies have shown an improvement of atopic dermatitis after treatment with CysLT\textsubscript{1} antagonists. Collectively, these findings suggest that LTE4-mediated ILC2 activation could be a critical contributor to allergic inflammation. This role might be particularly important in patients with aspirin-exacerbated asthma, in whom LTE4 overproduction and a clinical response to cysLT blockade are particularly obvious.

It has been well established that epithelial cytokines (IL-33, IL-25, and TSLP) are important stimulators for ILC2 responses, and the lipid mediator PGD2 is also a strong regulator of ILC2s in type 2 immunity. Here we have shown that cysLTs have multiple proinflammatory effects on ILC2 migration, apoptosis, and cytokine production. They not only elicited production of type 2 cytokines but also other proinflammatory cytokines, including IL-8, GM-CSF, CSF1, TNF-\textalpha, and amphiregulin. These cytokines could, orchestrating with type 2 cytokines, contribute to eosinophilic (GM-CSF and TNF-\textalpha), neutrophilic (IL-8, GM-CSF, and TNF-\textalpha), and tissue-remodeling (CSF1, TNF-\textalpha, and amphiregulin) effects during allergic inflammations. Such reactions can be confirmed in other types of cell systems inhibited by montelukast. The efficacies of cysLTs...
FIG 5. LTE₄ enhancement of effects of PGD₂ and epithelial cytokines on cytokine production by cultured ILC2s. Cytokine concentrations after ILC2 treatment with LTE₄ and PGD₂ alone or in combination (A) or LTE₄, IL-33, IL-25, and TSLP alone or in combination (B) in the presence (black bars) or absence (white bars) of montelukast. Cytokines were measured with the multiplex bead array. *P < .05 (n = 3).
were significantly higher than those of innate cytokines (IL-33, IL-25, and TSLP) but lower than that of PGD2 in human ILC2s in in vitro assays when using them individually, indicating the important role of cysLTs in human ILC2s. In in vitro studies the ILC2 response to the lipid mediators is much faster (ie, hours) than that to the epithelial cytokines (ie, days). However, the speed of these responses under physiologic conditions will also depend on the timing of enrichment of these stimulators at inflammatory sites. To confirm the role of cysLTs under arguably more physiologic conditions, we examined the effect on ILC2s of endogenously synthesized cysLTs from human mast cells. The ILC2 response to the mast cell supernatant was similar to that seen with exogenously synthesized cysLTs. The only difference was that the response to the mast cell supernatant could not be...
completely blocked by montelukast or by inhibition of cysLT synthesis. This could be caused by the presence of other active mediators released from activated mast cells, such as PGD₂. Thus cysLTs only partially deliver the stimulating signal from activated mast cells to ILC2s. CysLTs can also be generated by other cells of the innate immune system, such as basophils, eosinophils, and alveolar macrophages, after exposure to allergens, proinflammatory cytokines, and other stimuli during allergic inflammation and also transcellularly by platelet-adherent leukocytes in patients with aspirin-exacerbated asthma. Therefore cysLTs can contribute to IgE-independent innate responses of ILC2s. Given the association of tissue mast cells, basophils, and eosinophils with allergic dermatitis and asthma, the inhibition of cysLT-mediated ILC2 activation might provide a therapeutic opportunity for these diseases potentially when combined with other approaches.

Although cysLTs alone can activate ILC2s, the more pronounced effect was observed when they were used in combination with another lipid mediator (PGD₂) or epithelial cytokines (IL-33, IL-25, and TSLP). We suggest this effect is more representative of in vivo conditions in which, after allergen encounter, LTs and prostaglandins are simultaneously secreted by mast cells in parallel with IL-33, IL-25, and TSLP production by a compromised epithelium. Synergistic enhancement between LTE₄ and PGD₂ was also observed in human Tₐ₂ cells. Cross-enhancement of the effects of IL-25, IL-33, and TSLP has been reported in nasal epithelial and Tₐ₂ cells. However, the effect of cysLTs on the activity of epithelial cytokines is unknown. Here, for the first time, we reported that LTs markedly enhanced the effect of epithelial cytokines on ILC2 cytokine production. Our data demonstrated that the receptors for IL-33 and IL-25 were upregulated by the combination treatment and therefore might contribute to the enhanced effects. In keeping with this, we found a positive correlation between the degree of upregulation of IL1RL1 and enhancement of cytokine production under the same treatment. Further investigation is required to fully understand the mechanisms underlying this synergistic reaction.

**FIG 7.** Effect of endogenous cysLTs on cytokine production in cultured ILC2s. **A,** Levels of LTE₄ in supernatants of mast cells treated with medium (white bar, ns) or IgE/anti-IgE with (gray bar, IgE+MK) or without (black bar, IgE) MK886. **B** and **C,** Protein (Fig 7, **B**) and mRNA (Fig 7, **C**) levels of cytokines of ILC2s after incubation with supernatants with or without montelukast for 4 hours. *P < .05 (n = 4).
Another interesting observation is the promoting role of IL-2 on the ILC2 cytokine production in response to the combination of LTE4 and epithelial cytokines. IL-2 greatly improved the stimulatory effect of LTE4 in combination with IL-33, IL-25, and TSLP, whereas the effect of IL-2 on individual stimulator or on the combination of LTE4 and PGD2 was minimal. In vitro, IL-2 is required in the culture for ILC2 growth and proliferation. In vivo, it has been reported that IL-2 is a cofactor in regulating ILC2 function in pulmonary inflammation and coordinating type 2 cytokine expression in mouse models. Increased levels of IL-2 were detected in the lungs of asthmatic patients, and inhaled IL-2 therapy has been shown to induce asthma-like airway inflammation. Our data suggest a critical promoting effect of IL-2 on LTE4 and epithelial cytokine-induced activation of human ILC2s, which might be relevant to the pathogenesis of asthma and atopic dermatitis.

In summary, the present investigation highlights the multifaceted role of cysLTs, particularly LTE4, and their receptors in the activation of human ILC2s. They initiate production of type 2 cytokines in human ILC2s, which might be relevant to the pathogenesis of asthma and atopic dermatitis.

Key messages
- Human ILC2s express functional CysLT1, levels of which are increased in patients with atopic dermatitis.
- CysLTs are important activators of human ILC2s, and LTE4 is the most potent among the cysLTs.
- LTE4 synergistically enhances the effect of epithelial cytokines in human ILC2s through upregulation of IL-33/IL-25 receptors.

REFERENCES
1. Neill DR, Wong SH, Bellois A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010;464:3367-70.
2. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al. A role for IL-25 and IL-33-responsive type 2 innate lymphoid cells in atopic dermatitis. J Exp Med 2013;210:2393-50.
3. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011;12:1045-54.
4. Mjoqberg JM, Triflai S, Crellin NK, Peters CP, van Druenen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunity 2011;12:1055-62.
5. Kim BS, Siracusa MC, Saenz SA, Noti M, Monticelli LA, Sonenberg GF, et al. TSLP elicits IL-33/IL-25-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013;5:170ra16.
6. Chang YJ, Kim HW, Al-Ashker LA, Baumgart N, McKenzie AN, Smith DE, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunity 2011;12:631-8.
7. Xue L, Salimi M, Panse I, Mjoqberg JM, McKenzie AN, Spits H, et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 2014;133:1184-94.
8. Doeherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2 innate lymphoid cells express cytokine leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol 2013;132:205-13.
9. Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteiny1- leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med Res Rev 2007;27:469-527.
10. Singh RK, Gupta S, Dastidar S, Ray A. Cysteiny1 leukotrienes and their receptors: molecular and functional characteristics. Pharmacology 2010;85:336-49.
11. Sala A, Voelkle N, Maclouf J, Murphy RC. Leukotriene E(4) elimination and metabolism in normal human subjects. J Biol Chem 1990:265:21771-8.
12. Dzenz DR, O’Brien J, Sparrow D, Weiss ST, Martins MA, Israel E, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
13. Arm JP. Leukotriene generation and clinical implications. Allergy Asthma Proc 2004;25:37-42.
14. Xue L, Barlow A, Fleming VM, Hunter MG, Ogg G, Klenerman P, et al. Leukotriene E4 activates human TH2 cells for exaggerated proinflammatory cytokine production in response to prostaglandin D2. J Immunol 2012;188:694-702.
15. Xue L, Ferguson J, Salimi M, Panse I, Ussher JE, Hegazy AN, et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/ neutrophil crosstalk. J Allergy Clin Immunol 2015;135:1358-66, e1-11.
16. Lynch KR, O’Neill GP, Liu Q, Im DS, Sawyer N, Metters KM, et al. Characterization of the human cysteiny1 leukotriene CysLT1 receptor. Nature 1999;399:789-93.
17. Heise CE, O’Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im D-S, et al. Characterization of the human cysteiny1 leukotriene 2 receptor. J Biol Chem 2000;275:30531-6.
18. Paraciani S, Tashimo H, Feng C, Maaakawa A, Xing W, Jiang Y, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y2 receptor. J Exp Med 2009;206:2543-55.
19. Kanoaka Y, Maaakawa A, Austen KF. Identification of GPI99r protein as a potential third cysteinyl leukotriene receptor with a preference for leukotriene E4 ligand. J Biol Chem 2013;288:10967-72.
20. Busse W, Kraft M. Cysteiny1 leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005;127:1312-26.
21. Kim DC, Hsu FI, Barrett NA, Friend DS, Grenningloh R, Ho IC, et al. Cysteiny1 leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 2006;176:4440-8.
22. Parmentier CN, Fuerst E, McDonald J, Bowen H, Lee TH, Pease JE, et al. Human Th(H)2 cells respond to cysteiny1 leukotrienes through selective expression of cysteiny1 leukotriene receptor 1. J Allergy Clin Immunol 2012;129:1136-42.
23. Fregonese L, Silvestri M, Sabatini F, Rossi GA. Cysteiny1 leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism. Clin Exp Allergy 2002;32:745-50.
24. Woszczek G, Chen LY, Nagineni S, Kern S, Barb J, Munson PJ, et al. Leukotriene D4 induces gene expression in human monocytes through cysteiny1 leukotriene type I receptor. J Allergy Clin Immunol 2008;121:215-21.e1.
25. Bautz F, Denzlinger C, Kanz L, Mdrhe M. Chemoattractant and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1, Blood 2001;97:3435-40.
26. Lee E, Robertson T, Smith J, Kilefaher S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000;161:1881-6.
27. Lee E, Lindo T, Jackson N, Meng-Choon L, Reynolds P, Hill A, et al. Reversal of human neutrophil survival by leukotriene D4 receptor blockade and 5-lipoxygenase and 5-lipoxygenase activating protein inhibitors. Am J Respir Crit Care Med 1999;160:2079-85.
28. Roediger B, Kyle R, Tay SS, Mitchell AJ, Bolton HA, Guy TV, et al. IL-2 is a critical regulator of group 2 innate lymphoid cell function during pulmonary inflammation. J Allergy Clin Immunol 2015;136:1653-63.
29. Schleimer RP, Fox CC, Naciero RM, Plaut M, Creticos PS, Toigas AG, et al. Role of human basophils and mast cells in the pathogenesis of allergic diseases. J Allergy Clin Immunol 1985;76:369-74.
30. Foster HR, Fuerst E, Branchetti W, Lee TH, Cousins DJ, Woszczek G. Leukotriene E4 is a full functional agonist for human cysteiny1 leukotriene type 1 receptor-dependent gene expression. Sci Rep 2016;6:20461.
31. Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998;134:785-6.
32. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001;11:209-13.
33. Hon KL, Leung TF, Ma KC, Wong Y, Fok TF. Brief case series: montelukast, at doses recommended for asthma treatment, reduces disease severity and increases soluble CD14 in children with atopic dermatitis. J Dermatolog Treat 2005;16:15-8.
34. Fauler J, Neumann C, Tsikas D, Frölisch J. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 1993;128:627-30.
35. Rabinovitch N. Urinary leukotriene E4 as a biomarker of exposure, susceptibility and risk in asthma. Immunol Allergy Clin North Am 2012;32:433-45.
36. Macfarlane AJ, Dworski R, Sheller JR, Pavord ID, Kay AB, Barnes NC. Sputum cysteinyl-leukotrienes increase 24 hours after allergen inhalation in atopic asthmatics. Am J Respir Crit Care Med 2000;161:1553-8.
37. Laidlaw TM, Kidder MS, Bhattacharyya N, Xing W, Shen S, Milne GL, et al. Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes. Blood 2012;119:3790-8.
38. Wojno ED, Monticelli LA, Tran SV, Alenghat T, Osborne LC, Thome JJ, et al. The prostaglandin D2 receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol 2015;8:1313-23.
39. Caldenhoven E, van Dijk TB, Tijmensen A, Raaijmakers JA, Lammers JW, Koenderman L, et al. Differential activation of functionally distinct STAT3 proteins by IL-5 and GM-CSF during eosinophil and neutrophil differentiation from human CD34+ hematopoietic stem cells. Stem Cells 1998;16:397-403.
40. Mullol J, Callejas PB, Méndez-Arancibia E, Fuentes M, Abadí L, Martínez-Antón A, et al. Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival. J Biol Regul Homeost Agents 2010;24:403-11.
41. Henkels KM, Ronford K, Gonzalez-Mejia ME, Doseff AL, Gomez-Cambroner J. IL-8-induced neutrophil chemotaxis is mediated by Janus kinase 3 (JAK3). FEBS Lett 2011;585:159-66.
42. Wang YH, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells. J Exp Med 2007;204:1837-47.
43. Liao B, Cao PP, Zeng M, Zhen Z, Wang H, Zhang YN, et al. Interaction of thymic stromal lymphopoietin, IL-33, and their receptors in epithelial cells in eosinophilic chronic rhinosinusitis with nasal polyps. Allergy 2015;70:1169-80.
44. Oliphant CJ, Hwang YY, Walker JA, Salmi M, Wong SH, Brewer JM, et al. MHCIId-exuated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity 2014;41:283-95.
45. Loppow D, Huland E, Heinzner H, Grönke L, Magnussen H, Holz O, et al. Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. Eur J Med Res 2007;12:556-62.
METHODS

Reagents

LTC₄, LTD₄, LTE₄, and PGD₂ were purchased from Enzo Life Science (Farmingdale, NY). Lymphoprep was purchased from Axis-Shield UK (Dundee, United Kingdom). The RNasy Mini Kit and Omniscript Reverse Transcription Kit were supplied by Qiagen (Hilden, Germany). Real-time qPCR Master Mix and probes were from Roche (Mannheim, Germany). Primers were synthesized by Eurofins MWG Operon (Ebersberg, Germany). CD3 microbeads, the CD34 Microbead Kit, and anti-CRTH2 antibody were from Miltenyi Biotec (Bergisch Gladbach, Germany). Anti-human IL-13, CD3, CD19, CD45, and CD127 antibodies were from Biolegend (San Diego, Calif). Anti-human CD4, CD8, CD16, CD56, TCRαβ, TCRγδ, FcεRI, and IL-5 antibodies were from BioLegend (San Diego, Calif). Anti-human CD14 antibody was obtained from BD Biosciences. Anti-human CD11b and OXGR1 (GPR99) antibodies were from Abcam (Cambridge, United Kingdom). Anti-human CD11c antibody was from Life Technologies (Grand Island, NY). Anti-human CD123 antibody was from R&D Systems, and anti-human CysLTR1 antibody was from Novus Biologicals (Littleton, Colo). Recombinant human IL-2, IL-4, IL-25, IL-33, and TSLP were from PeproTech (Rocky Hill, NJ). Human IgE was purchased from Merck Millipore (Billerica, Mass). MK886 and montelukast were from Cayman Chemicals. Other chemicals were from Sigma-Aldrich (St Louis, Mo).

Western blotting

Cell lysates from ILC2s, Th2 cells, and NIH3T3 cells were prepared with a lysis buffer (20 mmol/L Tris-HCl [pH 7.4], 250 mmol/L sucrose, 1 mmol/L EDTA, 1 mmol/L ethyleneglycol-bis-[b-aminoethylether]-N,N,N9,N9-tetraacetic acid, 10 mmol/L sodium glycerophosphate, 50 mmol/L sodium fluoride, 5 mmol/L sodium pyrophosphate, 0.1% 2-mercaptoethanol, protease inhibitor mixture, and 1% Triton X-100). Lysates were fractionated by using SDS-PAGE on NuPAGE Novex 12% Bis-Tris Gels precast gels (Invitrogen). Western blot assays for GPR99 (OXGR1) were carried out on polyvinylidene difluoride membrane (iBlot stacks; Invitrogen).

Proliferation assay

Primary ILC2 cultures were washed with 0.1% BSA-PBS twice and resuspended in 500 μL of 0.1% BSA-PBS containing 5 μmol/L Cell Trace Violet (C34557, Life Technologies). After incubation at 37°C for 20 minutes, cells were washed twice with cold RPMI supplemented with 10% human serum. Labeled ILC2s were cultured in normal medium (RPMI 1640 containing 100 IU/mL IL-2, 10% heat-inactivated human serum, 2 mmol/L L-glutamine, 100 IU/mL penicillin, and 100 μg/mL streptomycin) without or with 100 nmol/L LTC₄, LTD₄, or LTE₄. Levels of Cell Trace Violet in the cells were measured and compared at days 1 and 4 with CyAn flow cytometry.

Intracellular cytokine staining

PBMCs were isolated from fresh blood and then stimulated with combinations of different cytokines and lipid mediators, as indicated, for 18 hours. Brefeldin A (3 μg/mL) was added during stimulation. Cells were washed twice with PBS. After cell-surface staining with lineage and CD45 antibodies and LiveDead staining, cells were permeabilized with a Cytofix/Cytoperm kit (BD), followed by staining with IL-5 (clone TRFK5) or IL-13 (clone 85BRD) antibodies. Then the cells were washed and fixed with 0.5% formaldehyde. Samples were analyzed with an LSR Fortessa flow cytometer.

Analysis of correlation

R values were calculated by using the Spearman test.
FIG E1. ILC2 isolation. ILC2s isolated from human blood were lineage marker negative (CD3, CD14, CD19, CD56, CD11c, CD11b, FcεRI, IL3R, TCRγδ and TCRαβ), CD45high, IL-7 receptor α-positive, and CRTH2+ cells. FSC, Forward scatter.
FIG E2. GPR99 is not expressed by human ILC2s and Th2 cells. The protein level of GPR99 in cell lysates was detected by using Western blotting. NIH3T3 cells were used as a positive control.
FIG E3. CysLTs do not affect proliferation of ILC2s in culture. Levels of Cell Trace Violet in ILC2s were measured with flow cytometry at day 4 after cell labeling with Cell Trace Violet and then incubation with 100 nmol/L LTC₄, LTD₄, or LTE₄ (n = 3).
FIG E4. LTE4 synergistically enhanced gene transcription of type 2 cytokines induced by PGD2 in cultured human ILC2s. mRNA levels of type 2 cytokines in ILC2s after treatment with LTE4 and PGD2 alone or their combination for 4 hours were determined by using quantitative RT-PCR.

*P < .05 (n = 3).
FIG E5. LTE₄ and PGD₂ enhanced the effects of epithelial cytokines on type 2 cytokine production by ILC2s ex vivo. A, IL-5⁺ ILC2s detected in fresh PBMCs after stimulation with IL-33 (50 ng/mL), IL-25 (50 ng/mL), and TSLP (50 ng/mL) or a combination of these epithelial cytokines with LTE₄ (50 nmol/L) and PGD₂ (100 nmol/L) by using intracellular staining. B, Proportion of type 2 cytokine (IL-5 and IL-13)–positive cells in gated Lin⁻CD45⁺ cells after indicated treatments. *P < .05. Data in Fig E5, A, are representative of 3 independent experiments (Fig E5, B, n = 3).
FIG E6. IL-2–enhanced cytokine production in ILC2s in response to LTE₄, IL-33, IL-25, and their combinations. IL-13 concentrations in ILC2 culture after incubation with LTE₄, IL-33, or IL-25 or their combinations in the presence (black bars) or absence (white bars) of IL-2 were measured with the multiplex bead array. *P < .05 (n = 3).
FIG E7. Effect of combination of IL-2 and other stimulators on gene expression of cytokines in ILC2 cells. mRNA levels of cytokines in cultured ILC2s after treatment with different combinations of LTE4, PGD2, IL-33, IL-25, and TSLP with or without montelukast in the presence (black bars) or absence (white bars) of IL-2 for 4 hours were measured with quantitative RT-PCR. *P < .05 (n = 3).
FIG E8. Relationship between *IL1RL1* gene regulation and cytokine productions in ILC2s after various treatments was analyzed by using Spearman analysis.

- **IL-5 (pg/ml)**: $R = 0.8927$ ($p < 0.0001$)
- **IL-13 (pg/ml)**: $R = 0.8968$ ($p < 0.0001$)
- **IL-8 (pg/ml)**: $R = 0.8865$ ($p < 0.0001$)
| Gene   | Primer 1  | Primer 2  | Probe no. |
|--------|-----------|-----------|-----------|
| IL3    | 5'-TTGCCCCTTTGCTGGAGCTTCA-3' | 5'-CTGGTGAATGCGCTCCAGGTT-3' | 60 |
| IL5    | 5'-GTTTTGTTTCAGCAGCAAAGAT-3' | 5'-CTTTGCCCCACCTTCCTACT-3' | 25 |
| IL8    | 5'-AGACAGAGAGAGACACAACAAAGC-3' | 5'-ATGTTCCCTCCGGTGTGT-3' | 72 |
| IL13   | 5'-AGCCCTCAGGAGACCTCAT-3' | 5'-CTCCATACACACGCTGCCCATT-3' | 17 |
| GMCSF  | 5'-TCTCAGAAATATTTGGACCTCCA-3' | 5'-GCCCTTTGAGCTTGGTGAG-3' | 1 |
| PTGDR2 | 5'-CCTGTGCTCCCTCTGTC-3' | 5'-TCTGGAGACGGGCACATCTG-3' | 43 |
| CYSLT1 | 5'-ACTCCAGTGCCAGAAGAGG-3' | 5'-GGGAAGTCATCAATAGTGA-3' | 29 |
| CYSLT2 | 5'-CTAGAGTCCTGCTGGCTGAAA-3' | 5'-GTAGGATCAATGCTTCTTC-3' | 48 |
| GPR99  | 5'-AACCTGTATTTGTAGCTACAT-3' | 5'-GGATAATCGTGATAGCAGAACACG-3' | 16 |
| IL1RL1 | 5'-TTGTCCTACCATGTGACCTCATACA-3' | 5'-GATCCCTGAAGAGCTGCAA-3' | 56 |
| IL2RA  | 5'-ACGGGAAGACCAAGGGTGAG-3' | 5'-GCCTGGAGCTTCTCTTC-3' | 54 |
| IL17RA | 5'-ACTCCCTCCTACCTGTC-3' | 5'-GACATGGGTTATTTGTGTT-3' | 85 |
| IL17RB | 5'-GCCTTTCCATGCTCGTGAAT-3' | 5'-CGCGGCTTGACACATTTT-3' | 64 |
| P2Y12  | 5'-TTTGCTAAACATAGTTCTGACC-3' | 5'-GGAAAGACCATTTCTACATCT-3' | 27 |
| GAPDH  | 5'-AGCCACATCGCTGACAC-3' | 5'-GCACCATAACGACCAATTCC-3' | 60 |

**GAPDH**, Glyceraldehyde-3-phosphate dehydrogenase.
### Table E2. Study subjects

|                        | Patients with atopic dermatitis (n = 8) | Healthy control subjects (n = 4) |
|------------------------|----------------------------------------|---------------------------------|
| Female/male sex        | 5/3                                    | 3/1                             |
| Age (y)                | 30-88                                  | 28-46                           |
| SCORAD score           | 5-70                                   | NA                              |

NA. Not applicable.